Welcome To Diurnal
Diurnal is a UK-based specialty pharmaceutical company dedicated to developing hormone therapeutics to aid lifelong treatment for rare and chronic endocrine conditions, including Congenital Adrenal Hyperplasia, Adrenal Insufficiency, Hypogonadism and Hypothyroidism.
The company has a strong, multi-skilled entrepreneurial management team with extensive pharmaceutical product development experience and an affiliated network of world-class clinical experts in the area of endocrinology.
Mission Statement
To address the major unmet clinical and patient needs in endocrinology by creating products for the lifelong treatment of chronic conditions.
Latest News
-
09 Jun2020
Chronocort® Phase 3 data to be presented at ENDO Online 2020
The presentation will be presented by Deborah P. Merke, MD, MS, from NIH Clinical Center and NICHD, Bethesda, MD, USA, at ENDO Online 2020.
-
15 Apr2020
Operational Update
Arrangements in place to ensure constant drug supply to patients across Europe
-
01 Apr2020
Diurnal’s European Marketing Authorisation Application for Chronocort® passes validation stage with EMA
European regulatory recommendation for approval targeted for Q1 2021